NeuroSearch to cut workforce by 20% as it focuses on Huntington's candidate
This article was originally published in Scrip
Executive Summary
NeuroSearch, which recently published promising results of a meta-analysis from two previous trials corroborating the potential of its Huntexil (pridopidine) to treat Huntington's disease, is cutting around 20% of its workforce and setting up a new division to house all its ion channel drug discovery and existing partner alliances.